Adam Lin
@drdradamlin.bsky.social
HSCT&Cell Therapy Physician | Nanotechnology and Biomaterials Lab for Blood Cancers | Lymphoma | Physician Scientist | Assistant Professor @NU & RHLCCC
Reposted by Adam Lin
Dr. Éliane Gluckman revolutionized #hematology by performing the 1st human cord blood transplant. Since then, there have been more than 40K transplants, with cord blood registries established worldwide. 🩸✨
Watch this video about her amazing career https://bit.ly/3DnxswP
#ASH24 #Hemesky
Watch this video about her amazing career https://bit.ly/3DnxswP
#ASH24 #Hemesky
- YouTube
Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.
bit.ly
December 30, 2024 at 12:39 PM
Dr. Éliane Gluckman revolutionized #hematology by performing the 1st human cord blood transplant. Since then, there have been more than 40K transplants, with cord blood registries established worldwide. 🩸✨
Watch this video about her amazing career https://bit.ly/3DnxswP
#ASH24 #Hemesky
Watch this video about her amazing career https://bit.ly/3DnxswP
#ASH24 #Hemesky
Reposted by Adam Lin
December 30, 2024 at 10:35 PM
Reposted by Adam Lin
Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT @ash-hematology.bsky.social #ASH24 #hematology #oncology www.onclive.com/view/orca-q-...
Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT
Orca-Q led to low rates of graft-vs-host disease and non-relapse mortality in high-risk hematologic malignancies undergoing allo-HCT.
www.onclive.com
December 16, 2024 at 8:31 PM
Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT @ash-hematology.bsky.social #ASH24 #hematology #oncology www.onclive.com/view/orca-q-...
Reposted by Adam Lin
🌡️ Fever of Unknown Origin (FUO) = temp >38.3C multiple times x 3 weeks without obvious cause
Infections: 20-40%.
Connective tissue disorders: 20%
Malignancy: 10-20%
Undiagnosed: 20%
Drugs (e.g., phenytoin): rare
#medsky #IMsky #internalmedicine #IDsky #hemeonc #hemesky #oncsky #rheumsky
Infections: 20-40%.
Connective tissue disorders: 20%
Malignancy: 10-20%
Undiagnosed: 20%
Drugs (e.g., phenytoin): rare
#medsky #IMsky #internalmedicine #IDsky #hemeonc #hemesky #oncsky #rheumsky
December 13, 2024 at 11:36 AM
Reposted by Adam Lin
Out in @bloodjournal during #ASH24 - cool work by @freemanlciaraMD @DrFredLocke et al looking at #MMsm CAR-T in myeloma:
MTV (by PET-CT), sBCMA, BMPC don't always correlate. Some MTV-high but sBCMA-low pts exist - may not respond durably to BCMA CAR-T.
ashpublications.org/blood/articl...
MTV (by PET-CT), sBCMA, BMPC don't always correlate. Some MTV-high but sBCMA-low pts exist - may not respond durably to BCMA CAR-T.
ashpublications.org/blood/articl...
December 13, 2024 at 6:49 PM
Out in @bloodjournal during #ASH24 - cool work by @freemanlciaraMD @DrFredLocke et al looking at #MMsm CAR-T in myeloma:
MTV (by PET-CT), sBCMA, BMPC don't always correlate. Some MTV-high but sBCMA-low pts exist - may not respond durably to BCMA CAR-T.
ashpublications.org/blood/articl...
MTV (by PET-CT), sBCMA, BMPC don't always correlate. Some MTV-high but sBCMA-low pts exist - may not respond durably to BCMA CAR-T.
ashpublications.org/blood/articl...
Reposted by Adam Lin
Staggering statistics at #ASH24 #TreatingFairly
Patients with cancer who go bankrupt are nearly 80% more likely to die regardless of disease status.
Our system quite literally kills people.
Patients with cancer who go bankrupt are nearly 80% more likely to die regardless of disease status.
Our system quite literally kills people.
December 8, 2024 at 12:17 AM
Staggering statistics at #ASH24 #TreatingFairly
Patients with cancer who go bankrupt are nearly 80% more likely to die regardless of disease status.
Our system quite literally kills people.
Patients with cancer who go bankrupt are nearly 80% more likely to die regardless of disease status.
Our system quite literally kills people.
Reposted by Adam Lin
Megan Melody presenting important data on bi specific antibodies after CAR T progression at ASH24
December 8, 2024 at 7:01 PM
Megan Melody presenting important data on bi specific antibodies after CAR T progression at ASH24
Reposted by Adam Lin
Wisdom doesn’t come from experience. It comes from reflecting on experience.
Between ages 25 and 75, the correlation between age and wisdom is zero.
Gaining insight and perspective is not about the number of years you've lived. It's about the number of lessons you've learned.
Between ages 25 and 75, the correlation between age and wisdom is zero.
Gaining insight and perspective is not about the number of years you've lived. It's about the number of lessons you've learned.
December 6, 2024 at 2:52 PM
Wisdom doesn’t come from experience. It comes from reflecting on experience.
Between ages 25 and 75, the correlation between age and wisdom is zero.
Gaining insight and perspective is not about the number of years you've lived. It's about the number of lessons you've learned.
Between ages 25 and 75, the correlation between age and wisdom is zero.
Gaining insight and perspective is not about the number of years you've lived. It's about the number of lessons you've learned.
Reposted by Adam Lin
Scientists have made major strides in engineering CAR-T cell therapies to treat autoimmune disorders such as lupus, according to a new #ScienceTranslationalMedicine Review that discusses the latest breakthroughs and clinical trials in the field. scim.ag/4f0RmL1
Engineering CAR-T therapies for autoimmune disease and beyond
Emerging CAR-T technologies offer transformative potential to address the needs of patients with autoimmunity or other diseases beyond cancer.
scim.ag
December 4, 2024 at 6:30 PM
Scientists have made major strides in engineering CAR-T cell therapies to treat autoimmune disorders such as lupus, according to a new #ScienceTranslationalMedicine Review that discusses the latest breakthroughs and clinical trials in the field. scim.ag/4f0RmL1
Reposted by Adam Lin
The possible “catastrophic success” of CAR-T cells in cancer and autoimmune disease @science.org. A nice story on dramatic diseases, biomedical technology and sustainability.. bit.ly/4i9FXf1 #oncosky #medsky #oncsky 🧪
A breakthrough cancer immunotherapy is now taking aim at autoimmune disease
CAR-T therapy is generating excitement for lupus, scleroderma, and other conditions as clinical trials expand
bit.ly
November 25, 2024 at 5:36 AM
The possible “catastrophic success” of CAR-T cells in cancer and autoimmune disease @science.org. A nice story on dramatic diseases, biomedical technology and sustainability.. bit.ly/4i9FXf1 #oncosky #medsky #oncsky 🧪
Reposted by Adam Lin
Such a thoughtful way to share thanks!
Writing holiday cards for our cancer patients who participate in research! @leonidasplatan1.bsky.social
November 27, 2024 at 12:11 AM
Such a thoughtful way to share thanks!